Skip to main content
Article thumbnail
Location of Repository

Challenges Associated with Scaling up Artemisinin Combination Therapy in Sub-Saharan Africa A Review Article

By J Njuguna and SS Qader

Abstract

Malaria is the leading cause of morbidity and mortality in Sub-Saharan Africa. One key strategic intervention is provision of early diagnosis and prompt effective treatment. A major setback has been the development of drug resistance to commonly used antimalarials. To overcome this, most countries in Sub-Saharan Africa have adopted Artemisinin Combination Therapy (ACT) as a first line treatment for uncomplicated malaria. Artemether Lumefantrine (AL) and Artesunate Amodiaquine (ASAQ) are the main drugs of choice. There are key implementation issues, which may have a bearing on the scaling up of this new treatment. This article reviewed the published papers on ACT with focus on sustainability, compliance, and diagnosis. ACTs are costly, but highly effective. Their scaling up is the most cost effective malaria intervention currently available. Most countries rely heavily on the Global Fund for their scaling up. AL has a short shelf life, a complicated six-dose regimen that requires intake with fat to ensure sufficient bioavailability. High rates of adherence have been reported. Use of parasitic diagnosis is advocated to ensure rational use. Parasitic diagnostics like rapid test and microscopy are currently inadequate. The majority of malaria cases may continue to be diagnosed clinically leading to over prescription of drugs. ACTs are currently not available at the community level for home based management of malaria. Issues related to safety and rational use need to be addressed before their use in the informal health sector like community drug sellers and community health workers. The majority of malaria cases at the community level could go untreated or continue to be treated using less effective drugs. We conclude that ACTs are highly effective. A major challenge is ensuring rational use and access at the household level. It is hoped that addressing these issues will increase the likelihood that ACT achieves its intended goals of reducing morbidity and mortality due to malaria, and delaying the onset of drug resistance

Topics: Review Article
Publisher: CoAction Publishing
OAI identifier: oai:pubmedcentral.nih.gov:3074329
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1999). A comparison of Amodiaquine and sulphadoxinepyrimethamine as first line treatment of falciparum malaria in Kenya. Trans R Soc Trop Med Hyg.
    2. (2007). A cost-effectiveness analysis of Artemether Lumefantrine for treatment of uncomplicated malaria in Zambia. Malar J.
    3. A randomised comparison of Artemether- benflumetol and artesunate-mefloquine in the treatment of multi-drug resistant falciparum malaria. Antimicrob Agent Chemother.1998;
    4. (2004). Adherence to a combination of Artemether and Lumefantrine (Coartem®) in Keji, Southern Sudan. Ann Trop Med Parasitol.
    5. (2004). Adherence to a six-dose regimen of Artemether-Lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J Trop Med Hyg.
    6. (2004). Adherence to antimalarial combination therapy with sulfadoxine-pyrimethamine and artesunate in rural Tanzania. Am J Trop Med Hyg.
    7. (2004). Adherence to the combination of sulfadoxine-pyrimethamine and artesunate in the Maheba Refugee Settlement, Zambia. Trop Med Int Health.
    8. (2005). Artemisinin based Combination Therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! Acta Tropica.
    9. (2004). Artemisinin Combination Therapy reduces expenditure on Malaria treatment in Kwa Zulu Natal, South Africa. Trop Med Int Health.
    10. (2005). Artemisininbased combination treatment in home –based management of malaria. Trop Med Int Health.
    11. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agent Chemother.1997;
    12. (2005). Bacteremia among children admitted to a rural hospital in Kenya. New England Journal of Medicine.
    13. Beyond registration—measuring the public health potential of new treatments for malaria in Africa. Lancet Ifect Dis.2006;
    14. (2006). Can malaria be controlled where basic health services are not used? Trop Med Int Health.
    15. (2002). Changing national malaria treatment protocols in Africa: What is the cost and who will pay? Case studies:
    16. (2002). Chlorproguanil-dapsone versus sulfadoxine – pyrimethamine for sequential episodes of uncomplicated Page 47www.ljm.org.ly Review Article Libyan J Med, AOP: 071204 falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet.
    17. (2005). Cost effectiveness analysis of strategies to combat malaria in developing countries.
    18. (2006). Costeffectiveness study of three antimalarial drug combinations in Tanzania. PLoS Med.
    19. (2007). Drugs for Neglected diseases Initiative. ASAQ in a few words. Accessed
    20. (2005). Efficacy and safety of Artemether-Lumefantrine (Coartem®) tablets (six dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg.
    21. (2000). Expert Committee on Malaria, Twentieth Report.
    22. (2006). Feasibility and acceptability of the use of Artemether Lumefantrine in the home management of uncomplicated malaria in children 6-59 months old in Ghana. Trop Med Int Health.
    23. (2006). for the treatment of malaria.
    24. (2007). How much fat is necessary to optimize Lumefantrine oral bioavailability? Trop Med Int Health.
    25. (2004). Improving malaria treatment by training drug retailers in rural Kenya. Trop Med Int Health.
    26. (1997). Malaria and Human Immunodeficiency virus infection among male employees of a sugar estate in Malawi. Trans R Soc Trop Med Hyg.
    27. (2004). Malaria misdiagnosis: effects on the poor and vulnerable. Lancet.
    28. (2006). Microscopy and outpatient malaria case management among older children and adults in Kenya. Trop Med Int Health.
    29. (1988). Organisation. Malaria diagnosis: Memorandum from a WHO meeting. Bull World Health Organ.
    30. (2006). Over-diagnosis of malaria is not a lost cause. Malar Journal.
    31. overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study.
    32. (2007). Paediatric malaria case-management with Artemether Lumefantrine in Zambia: a repeat cross sectional study. Malar J.
    33. (1997). Preventing antimalarial drug resistance through combinations. Drug Resistance Updates.
    34. (2007). Rollback Malaria available at: www.rollbackmalaria.org/amd2006/ Accessed
    35. (2000). Saving lives, buying time: economics of malaria drugs an age of resistance. Washington DC:
    36. (2001). Severe allergic reactions to oral artesunate: a report of 2 cases. Trans R Soc Trop Med Hyg.
    37. (2005). Should artemisininbased combination treatment be used in the home-based management of malaria? Trop Med Int Health.
    38. (2006). Sixth Malaria Day in 2006: How far have we come after Abuja Declaration? Malar J.
    39. (2004). Special Programme for Research and Training in Tropical Diseases. Social science research on tropical diseases (CD ROM).
    40. (2005). Supervised versus unsupervised intake of six-dose Artemether-Lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet.
    41. (2000). Teaching mothers to provide home treatment of malaria in Tigray, Ethiopia: a randomised trial. Lancet.
    42. (2003). The Africa malaria report
    43. (1997). The Bamako Initiative in Benin and Guinea: improving the effectiveness of primary health care. Int J Health Plann Manage.
    44. (2007). The challenges of changing national malaria drug policy to artemisinin- based combinations in Kenya. Malaria journal.
    45. (2001). The Health workers for change impact study in Kenya. Health Policy and Planning.
    46. (2007). The heat stability of Plasmodium lactate dehydrogenase- based and histidine rich protein 2- based malaria rapid diagnostic tests. Trans R Soc Trop Med Hyg.
    47. (2003). The public health burden of Plasmodium falciparum malaria in Africa: Deriving the number.
    48. (2003). The use of formal and informal curative services in the management of paediatric fever in 4 districts in Kenya. Trop Med Int Health.
    49. (2007). Treatment of malaria restricted to laboratoryconfirmed cases: a prospective cohort in Ugandan children. Malar J.
    50. (2005). Treatment of paediatric malaria during a period of drug transition to Artemether-Lumefantrine in Zambia: a cross sectional study. BMJ.
    51. (2002). Use of clinical algorithms for diagnosing malaria. Trop Med Int Health.
    52. (2007). What is the Roll Back Malaria Partnership?
    53. (2005). WHO combats counterfeit drugs in Asia. BMJ.
    54. (2007). World Health Organization .Procurement of ArtemetherLumefantrine through the WHO Available at http://www.who.int/malaria/cmc_upload/0/000/015/789/CoA_we bsite5.pdf Accessed:

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.